Three months after Mylan NV moved on to Meda AB of Sweden with Cravath, Swaine & Moore in tow, the generic drug giant has again retained the firm to advise on its proposed $1 billion acquisition of the dermatology division of Renaissance Acquisition Holdings LLC, a portfolio company of Lake Forest, Illinois-based private equity firm RoundTable Healthcare Partners LP.
The deal, announced Friday, will see Mylan pay $950 million to RoundTable at closing, and up to $50 million more in contingency payments. Reuters reported that Renaissance, which has 50 products (half in development), generated revenues of $370 million last year.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
